Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.
Roche lifted the Swiss drugmaker’s 2019 sales target for the third time during the year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation’s annual deaths.
A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of the company’s talc-based products for feminine hygiene.
Indianapolis-based Eli Lilly announced the closing of the company’s Surrey, U.K.-based Erl Wood neuroscience research center by the end of 2020, affecting 270 staffers.
Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.
If there was one song that could be the pharma industry’s anthem during 2018-2019, it would be the David Bowie/Freddie Mercury hit “Under Pressure.” With the Trump administration’s and Congress’ efforts to reign in drug prices, pharma executives have a lot to keep them up at night.
Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November 2019 in the country’s eastern provinces, to counter the current outbreak.
Five Prime Therapeutics Inc. will eliminate 70 jobs while undergoing a restructuring to extend the company’s cash runway.
Roche Vice Chairman Andre Hoffman is warning that short-term thinking is killing the planet and that corporations must engage in long-term sustainable strategies that limit any environmental harm.
Purdue Pharma LP will ask a U.S. Bankruptcy Judge to pause litigation against the company and ownership over the objections of U.S. states that allege the OxyContin maker is trying to protect the controlling Sackler family.
